Article Text

Download PDFPDF
Correlation of rate of serum albumin decline with other acute phase reactants and effect of current treatment options on serum albumin level in COVID-19
  1. Simrat Kaur Batth
  1. Punjab Institute of Medical Sciences, Jalandhar, Punjab, India
  1. Correspondence to Dr Simrat Kaur Batth, Punjab Institute of Medical Sciences, Jalandhar 144006, Punjab, India; simratbatth6062{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Dear Editor,

I have read the study “ALLY in fighting COVID-19: magnitude of albumin decline and lymphopenia (ALLY) predict progression to critical disease”1 with great interest but would like to bring some issues to the notice of the readers.

First, the study used a comorbidity score to calculate the number of comorbidities present at admission out of asthma, coronary artery disease, chronic obstructive pulmonary disease, diabetes mellitus, hypertension, cancer, history of renal disease, and smoking.1 ⁠ Liver disease has not been considered in the comorbidity scale, which can greatly …

View Full Text


  • Contributors SKB, being the sole author, is responsible for the preparation of the entire manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles